" stem cell research and organ repair" is listed as the "14th Five-Year Plan" National Key R&D Plan. Since the 14th Five-Year Plan period, my country's new stem cell drug research and development has advanced at a new speed. In order to encourage the development of new drugs and improve the efficiency of new drug approval, my country has gradually launched a new drug clinical default approval system. According to the latest data from CDE, 29 new stem cell drug projects in my country have obtained clinical default licenses, including placenta , umbilical cord, bone marrow and fat, etc. The indications involved include osteoarthritis, ischemic stroke, graft-versus-host disease, inflammatory bowel disease, diabetic foot ulcer, idiopathic pulmonary fibrosis, acute respiratory distress syndrome, ankylosing spondylitis, burns, severe lupus nephritis, etc. This has promoted the clinical application process of stem cells in my country to a certain extent and provided guarantee for the rapid development of the stem cell medical industry.
Today, we will take a look at 29 IND clinical projects for you. Let me tell you about the development of new stem cell drugs in my country.
